Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467037 | 0.88 | MTNR1A (0.38) | HTR1AMTNR1AMTNR1BTAS1R3TAS1R1 | |
| SCHEMBL5478308 | 0.77 | TRPV1 (0.41) | MTNR1AMTNR1BTAS1R3TAS1R1PDPK1 | |
| SCHEMBL5476405 | 0.73 | NR3C1 (0.37) | — | |
| SCHEMBL5175482 | 0.73 | NR3C1 (0.37) | — | |
| SCHEMBL5476398 | 0.73 | NR3C1 (0.37) | — | |
| SCHEMBL5477889 | 0.71 | MTNR1A (0.38) | HTR1AMTNR1AMTNR1BTAS1R3TAS1R1 | |
| SCHEMBL5478156 | 0.69 | PDPK1 (0.42) | HTR1ATAS1R3TAS1R1TAS1R2OPRM1 | |
| SCHEMBL5472058 | 0.68 | HTR1A (0.44) | HTR1ATAS1R3TAS1R1TAS1R2PDPK1 | |
| SCHEMBL10360561 | 0.64 | GRIN2B (0.43) | DRD2SIGMAR1 | |
| SCHEMBL5473120 | 0.64 | TRPV1 (0.46) | MTNR1AMTNR1BPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | HTR1A 660/4885MTNR1A 2122/4885MTNR1B 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.